Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy

Trial Profile

Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Everolimus (Primary) ; Cisplatin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms NECTAR
  • Most Recent Events

    • 07 Oct 2015 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 07 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 03 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top